Literature DB >> 20658749

Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.

Fiona C Lampe1, Daniel A Duprez, Lewis H Kuller, Russell Tracy, James Otvos, Erik Stroes, David A Cooper, Jennifer Hoy, Nick I Paton, Nina Friis-Møller, Jacquie Neuhaus, Angelike P Liappis, Andrew N Phillips.   

Abstract

BACKGROUND: The effect of interruption of antiretroviral therapy (ART) on lipoprotein particle subclasses has not been studied. We examined short-term changes in lipids and lipoprotein particles among 332 HIV-infected individuals randomized to interrupt or continue ART in the "Strategies for Management of Antiretroviral Therapy" trial.
METHODS: Lipids and lipoprotein particles measured by nuclear magnetic resonance spectroscopy were compared between randomized groups at month 1; associations with inflammatory and coagulation markers (high sensitivity C-reactive protein; interleukin 6; amyloid A; amyloid P; D-dimer; prothrombin fragment 1 + 2) were assessed.
RESULTS: Compared with continuation of ART, treatment interruption resulted in substantial declines in total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglyceride, at month 1 but had little net effect on total/HDL cholesterol ratio [baseline-adjusted mean difference [95% confidence interval (CI)] interruption versus continuation arms: -0.10 (-0.59 to 0.38); P = 0.67]. ART interruption resulted in declines in total, large, and medium very low density lipoprotein (VLDL) particle concentrations (VLDL-p) and total and medium HDL-p. However, there was no change in small HDL-p [baseline-adjusted percentage difference between arms: -4.6% (-13.1%, +5.1% ); P = 0.35], small LDL-p [-5.0% (-16.9%, +8.6%); P = 0.45], or other LDL-p subclasses. Changes in lipid parameters on ART interruption did not differ according to baseline ART class (protease inhibitor versus non-nucleoside reverse transcriptase inhibitor) but were negatively associated both with changes in HIV viral load and with changes in inflammatory and coagulation markers, particularly D-dimer.
CONCLUSIONS: These results suggest that ART interruption does not favorably influence overall lipid profile: there was little net effect on total/HDL cholesterol ratio, and no change in small LDL-p or small HDL-p, the lipoprotein particle subclasses most consistently linked to coronary risk. Short-term declines in lipid parameters after ART interruption were not associated with class of ART and may be linked to increases in viral replication, inflammation and coagulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20658749      PMCID: PMC3117147          DOI: 10.1097/qai.0b013e3181d32158

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  38 in total

1.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

Authors:  C D Gardner; S P Fortmann; R M Krauss
Journal:  JAMA       Date:  1996-09-18       Impact factor: 56.272

2.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

3.  Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

Authors:  Kathleen Squires; Adriano Lazzarin; José M Gatell; William G Powderly; Vadim Pokrovskiy; Jean-François Delfraissy; Joseph Jemsek; Antonio Rivero; Willy Rozenbaum; Shannon Schrader; Michael Sension; Asda Vibhagool; Alexandra Thiry; Michael Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-15       Impact factor: 3.731

4.  A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

Authors:  Mark Dybul; Elizabeth Nies-Kraske; Robin Dewar; Frank Maldarelli; Claire W Hallahan; Marybeth Daucher; Stephen C Piscitelli; Linda Ehler; Ann Weigand; Sarah Palmer; Julia A Metcalf; Richard T Davey; Diane M Rock Kress; April Powers; Ingrid Beck; Lisa Frenkel; Michael Baseler; John Coffin; Anthony S Fauci
Journal:  J Infect Dis       Date:  2004-05-10       Impact factor: 5.226

5.  Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation.

Authors:  R Zangerle; M Sarcletti; H Gallati; G Reibnegger; H Wachter; D Fuchs
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-11

6.  Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.

Authors:  Franco Maggiolo; Diego Ripamonti; Gianpietro Gregis; Gianpaolo Quinzan; Annapaola Callegaro; Fredy Suter
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

7.  Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

Authors:  E Fontas; F van Leth; C A Sabin; N Friis-Møller; M Rickenbach; A d'Arminio Monforte; O Kirk; M Dupon; L Morfeldt; S Mateu; K Petoumenos; W El-Sadr; S de Wit; J D Lundgren; C Pradier; P Reiss
Journal:  J Infect Dis       Date:  2004-03-02       Impact factor: 5.226

8.  EDTA-plasma vs serum differences in cholesterol, high-density-lipoprotein cholesterol, and triglyceride as measured by several methods.

Authors:  I Beheshti; L M Wessels; J H Eckfeldt
Journal:  Clin Chem       Date:  1994-11       Impact factor: 8.327

9.  Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy.

Authors:  Patrick M Tarwater; Michelle Parish; Joel E Gallant
Journal:  Clin Infect Dis       Date:  2003-11-06       Impact factor: 9.079

10.  Lipid concentrations in serum and EDTA-treated plasma from fasting and nonfasting normal persons, with particular regard to high-density lipoprotein cholesterol.

Authors:  A R Folsom; K Kuba; R V Leupker; D R Jacobs; I D Frantz
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

View more
  7 in total

Review 1.  Lipid Abnormalities and Inflammation in HIV Inflection.

Authors:  Nicholas T Funderburg; Nehal N Mehta
Journal:  Curr HIV/AIDS Rep       Date:  2016-08       Impact factor: 5.071

2.  Short communication: risk of elevated total cholesterol/high-density lipoprotein cholesterol ratio after antiretroviral therapy in HIV/hepatitis C virus patients.

Authors:  Lisa Kakinami; Michael J Adams; Robert C Block; Susan E Cohn; Benedict Maliakkal; Susan G Fisher
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-10       Impact factor: 2.205

3.  Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

Authors:  Petra El Khoury; Mathilde Ghislain; Elise F Villard; Wilfried Le Goff; Caroline Lascoux-Combe; Patrick Yeni; Laurence Meyer; Corinne Vigouroux; Cécile Goujard; Maryse Guerin
Journal:  J Lipid Res       Date:  2015-01-08       Impact factor: 5.922

4.  The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study.

Authors:  Honor Rose; Hann Low; Elizabeth Dewar; Michael Bukrinsky; Jennifer Hoy; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2013-04-17       Impact factor: 5.162

5.  HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.

Authors:  Katleen de Gaetano Donati; Roberto Cauda; Licia Iacoviello
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-11-11       Impact factor: 2.576

Review 6.  Acute coronary syndromes in patients with HIV.

Authors:  Valmiki K Seecheran; Stanley L Giddings; Naveen A Seecheran
Journal:  Coron Artery Dis       Date:  2017-03       Impact factor: 1.439

7.  Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection.

Authors:  Tatiana V Kirichenko; Veronika A Myasoedova; Tatiana E Shimonova; Alexandra A Melnichenko; Dmitri Sviridov; Igor A Sobenin; Alexey I Mazus; Alexander N Orekhov; Michael I Bukrinsky
Journal:  Biosci Rep       Date:  2018-07-18       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.